@tompowles1 Why do we now accept ~70-80% g3 AEs with IO + TKI's but the same relative toxicity with combining sunitinib or pazopanib to nivolumab was felt to be a "high incidence of high-grade toxicities limiting future development of either combination re
375 followers
565 followers
@VPrasadMDMPH @Plenary_Session @DrKarineTawagi Yes I like the CCTG idea, but interestingly early phase trials of sunitinib + ICI demonstrated high rates of toxicity. The specific TKI partner seems to be important.. https://t.co/iOaEyOK2P5
132 followers
14,230 followers